Heart valve disease represents a diverse spectrum of conditions that pose significant challenges to cardiovascular health. While some cases of valve disease may remain asymptomatic for a long time, others can progress to severe complications, including heart failure. The management of heart valve disease often involves a collaborative effort among cardiologists, cardiac surgeons, and other healthcare professionals. Advances in medical technology have led to the development of less invasive procedures, such as transcatheter aortic valve replacement (TAVR), providing viable options for certain patients who may not be suitable candidates for traditional open-heart surgery. Ongoing research aims to enhance our understanding of the underlying mechanisms of valve disease and explore novel therapeutic approaches. Regular monitoring, early intervention, and personalized treatment plans are crucial elements in the comprehensive care of individuals with heart valve disease, emphasizing the importance of a multidisciplinary and patient-centered approach in addressing the complexities of this cardiovascular condition.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India